Evidence map›Paper›PMID 42545082›Full record

ArticleAntimicrobial agents and chemotherapy2026

Oral lipid prodrug V2043 (1-

Alex E Clark, Jonathan R Erlich, James R Beadle, Rachel E McMillan, Jialei Xie, Aaron F Garretson, Shae Atkins, Anoushka Sharma, Suraj Manohar Rajan, Ben A Croker and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alex E Clark *Department of Pathology, University of California San Diego, La Jolla, California, USA.ORCID 0000-0003-1687-416X
Jonathan R Erlich *Department of Pediatrics, University of California San Diego, La Jolla, California, USA.
James R BeadleDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Rachel E McMillanDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Jialei XieDepartment of Pathology, University of California San Diego, La Jolla, California, USA.
Aaron F GarretsonDepartment of Pathology, University of California San Diego, La Jolla, California, USA.
Shae AtkinsDepartment of Pathology, University of California San Diego, La Jolla, California, USA.
Anoushka SharmaDepartment of Pathology, University of California San Diego, La Jolla, California, USA.
Suraj Manohar RajanDepartment of Pathology, University of California San Diego, La Jolla, California, USA.
Ben A CrokerDepartment of Pediatrics, University of California San Diego, La Jolla, California, USA.
Robert T SchooleyDepartment of Medicine, University of California San Diego, La Jolla, California, USA.ORCID 0000-0002-2498-8426
Karl Y HostetlerDepartment of Medicine, University of California San Diego, La Jolla, California, USA.ORCID 0000-0002-1155-2885
Aaron F CarlinDepartment of Pathology, University of California San Diego, La Jolla, California, USA.ORCID 0000-0002-1669-8066

Funding

Optimizing lipid RVn monophosphate prodrugs to maximize RVn-triphosphate deliveryR01AI187899 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CARLIN, AARON F. · 2025 to 2025
$3.1M
Revising Anti-coronavirus Compounds to Enhance Activity and Optimize DeliveryR01AI161348 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Karl Y Hostetler, Robert Turner Schooley · 2021 to 2026
$3.1M
UC San Diego Genetics Training ProgramT32GM145427 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRUCE A HAMILTON · 2022 to 2026
$2.6M
Bill and Melinda Gates Foundation INV-049940National Institute of Allergy and Infectious Diseases R01 AI161348National Institute of Allergy and Infectious Diseases R01 AI187899NIAID NIH HHS R01 AI161348NIAID NIH HHS R01 AI187899NIGMS NIH HHS T32 GM145427
6 · The paper itself

Abstract

Dengue virus and related flaviviruses are significant threats to global health, with no approved antiviral treatments available. Remdesivir triphosphate (RVn-TP) is a nucleotide analog that inhibits RNA-dependent RNA polymerases from many clinically important RNA viruses, including dengue virus. An orally bioavailable prodrug that efficiently delivers RVn-TP could facilitate early treatment for non-hospitalized dengue patients. To that end, we developed 1-

Indexed as

Adenosine MonophosphateAlanineAntiviral AgentsDengueProdrugsAdministration, OralAnimalsChlorocebus aethiopsDengue VirusFemaleHumansMiceVirus ReplicationWest Nile virusZika VirusAdenosine MonophosphateAlanineAntiviral AgentsProdrugsremdesivirbroad spectrum antiviraldenguein vivo efficacyJapanese encephalitis viruslipid prodrugmouse modelremdesivirremdesivir nucleosideWest Nile virusZika virus

Identifiers

PMID42545082
PMCPMC13604564

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.